SCHEMBL2464584

SCHEMBL2464584

Cc1ccc(N2CCCCC2)c2c1C(=O)c1ccccc1C2=O

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ L3MBTL1 Q9Y468 7/20 0.74
▸ NSD2 O96028 4/20 0.74
▸ LMNA P02545 4/20 0.74
▸ MAPT P10636 10/20 0.62
▸ MAPK1 P28482 6/20 0.62
▸ ALDH1A1 P00352 4/20 0.62
▸ EGFR P00533 2/20 0.62
▸ RAF1 P04049 1/20 0.62
▸ ALOX12 P18054 1/20 0.62
▸ MAP2K1 Q02750 1/20 0.62
▸ KMT2A Q03164 5/20 0.55
▸ TDP1 Q9NUW8 5/20 0.55
▸ POLB P06746 4/20 0.55
▸ MEN1 O00255 3/20 0.55
▸ THRB P10828 2/20 0.55
▸ S100A4 P26447 1/20 0.55
▸ SMN1; SMN2 Q16637 5/20 0.51
▸ NPSR1 Q6W5P4 4/20 0.51
▸ KDM4E B2RXH2 1/20 0.51
▸ USP2 O75604 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3273424 0.79 MAPT (0.97) L3MBTL1NSD2LMNAMAPTMAPK1
SCHEMBL55743 0.77 ALDH1A1 (0.67) L3MBTL1NSD2LMNAMAPTMAPK1
SCHEMBL30886455 0.77 ALDH1A1 (0.67) L3MBTL1NSD2LMNAMAPTMAPK1
SCHEMBL2463193 0.77 MAPT (1.00) L3MBTL1NSD2LMNAMAPTMAPK1
SCHEMBL2466648 0.76 MAPT (0.54) L3MBTL1NSD2LMNAMAPTMAPK1
SCHEMBL16281847 0.75 ALDH1A1 (0.66) L3MBTL1NSD2LMNAMAPTMAPK1
SCHEMBL14983925 0.73 L3MBTL1 (0.82) L3MBTL1NSD2LMNAMAPTMAPK1
SCHEMBL9267831 0.73 ALDH1A1 (0.62) L3MBTL1NSD2LMNAMAPTMAPK1
SCHEMBL14422840 0.72 MAPT (1.00) L3MBTL1NSD2LMNAMAPTMAPK1
SCHEMBL2462677 0.72 MAPT (0.54) L3MBTL1NSD2LMNAMAPTMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20190022100-A1 ANTIVIRAL COMPOUNDS AND METHODS OF USE THEREOF TRANA DISCOVERY INC (US) 2019-01-24 — — US disclosed
US-20190022100-A1 ANTIVIRAL COMPOUNDS AND METHODS OF USE THEREOF TRANA DISCOVERY INC (US) 2019-01-24 — — US disclosed
US-10098887-B2 Antiviral compounds and methods of use thereof TRANA DISCOVERY, INC. (US) 2018-10-16 — — US disclosed
US-20160129006-A1 ANTIVIRAL COMPOUNDS AND METHODS OF USE THEREOF TRANA DISCOVERY INC (US) 2016-05-12 — — US disclosed
US-20160129006-A1 ANTIVIRAL COMPOUNDS AND METHODS OF USE THEREOF TRANA DISCOVERY INC (US) 2016-05-12 — — US disclosed
US-20160129006-A1 ANTIVIRAL COMPOUNDS AND METHODS OF USE THEREOF TRANA DISCOVERY INC (US) 2016-05-12 — — US disclosed
US-9173886-B2 Antiviral compounds and methods of use thereof TRANA DISCOVERY, INC. (US) 2015-11-03 — — US disclosed
US-9173886-B2 Antiviral compounds and methods of use thereof TRANA DISCOVERY, INC. (US) 2015-11-03 — — US disclosed
US-9173886-B2 Antiviral compounds and methods of use thereof TRANA DISCOVERY, INC. (US) 2015-11-03 — — US disclosed
US-20130071353-A1 Antiviral Compounds and Methods of Use Thereof TRANA DISCOVERY, INC (US) 2013-03-21 — — US disclosed
US-20130071353-A1 Antiviral Compounds and Methods of Use Thereof TRANA DISCOVERY, INC (US) 2013-03-21 — — US disclosed
US-20130071353-A1 Antiviral Compounds and Methods of Use Thereof TRANA DISCOVERY, INC (US) 2013-03-21 — — US disclosed
WO-2011113060-A2 ANTIVIRAL COMPOUNDS AND METHODS OF USE THEREOF TRANA DISCOVERY, INC. (US) 2011-09-15 — — WO disclosed
WO-2011113060-A2 ANTIVIRAL COMPOUNDS AND METHODS OF USE THEREOF TRANA DISCOVERY, INC. (US) 2011-09-15 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10098887-B2 Antiviral compounds and methods of use thereof TYMP, MAVS, ZC3HAV1 L3MBTL1 528/4885NSD2 899/4885LMNA 2558/4885
US-20160129006-A1 ANTIVIRAL COMPOUNDS AND METHODS OF USE THEREOF TYMP, MAVS, ZC3HAV1 L3MBTL1 528/4885NSD2 899/4885LMNA 2558/4885
US-20130071353-A1 Antiviral Compounds and Methods of Use Thereof TYMP, MAVS, ZC3HAV1 L3MBTL1 528/4885NSD2 899/4885LMNA 2558/4885
US-20190022100-A1 ANTIVIRAL COMPOUNDS AND METHODS OF USE THEREOF TYMP, MAVS, ZC3HAV1 L3MBTL1 528/4885NSD2 899/4885LMNA 2558/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback